Cullinan oncology news
WebApr 13, 2024 · This is a summary of recent ratings and price targets for TScan Therapeutics and its competitors, as reported by MarketBeat. TScan Therapeutics currently has a consensus target price of $15.00 ... WebCAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc.(Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced clinical and regulatory updates on its lead program, CLN-081.
Cullinan oncology news
Did you know?
WebApr 12, 2024 · According to analysts' consensus price target of $34.50, Cullinan Oncology has a forecasted upside of 243.3% from its current price of $10.05. Amount of Analyst Coverage Cullinan Oncology has only been the subject of 2 research reports in the past 90 days. See Top Rated MarketRank™ Stocks Here About Cullinan Oncology … WebNov 2, 2024 · Cullinan Oncology, Inc. CAMBRIDGE, Mass., Nov. 02, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan Oncology”), a biopharmaceutical company focused on...
WebCAMBRIDGE, Mass., June 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that the U.S. Food and Drug Administration (FDA) has cleared Cullinan MICA’s IND application for CLN-619. CLN-619 is a first-in … WebMar 17, 2024 · Cullinan will provide a regulatory update on CLN-081 on March 28th, 2024. CLN-049 (Florentine): CLN-049 is a FLT3/CD3-bispecific T cell-engaging antibody in an …
WebCAMBRIDGE, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced the closing of WebApr 14, 2024 · The goal of this activity is for the learner to be better able to individualize care for patients with non-small cell lung cancer (NSCLC) and molecular alterations as part of the interprofessional team. Upon completion of this activity, participants will: Have increased knowledge regarding the. Clinical trial data evaluating targeted therapies ...
WebMar 27, 2024 · CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) --Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CLN …
WebMar 30, 2024 · CAMBRIDGE, Mass., March 30, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc.(Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced its financial results for the full year ended December 31, 2024 and reported on recent business highlights. freezing fresh potatoes from the gardenWebCullinan Oncology, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to … fast and furious guy who died in car crashWebWith patient benefit as our priority, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal … fast and furious happy birthdayWebAbout Cullinan Oncology Cullinan Oncology, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement … fast and furious han actorWebFeb 22, 2024 · CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announces the following business updates: Based on pre-specified efficacy … fast and furious hakafast and furious hahnWebView all updates, news, and articles Join now Similar pages Taiho Pharmaceutical Co., Ltd., ... Cullinan Oncology is dedicated to creating new standards of care for patients with … fast and furious han auto